Related Experiment Video
Updated: Jan 24, 2026

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
Published on: March 30, 2018
Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma
Linqing Zou1, Guoqi Song2, Siyu Gu1
1Department of Medicine, Nantong University, Nantong, Jiangsu 226001, China.
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treat DLBCL, the current first-line treatment is R-CHOP regimen. This regimen greatly improves patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to the resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exac mechanisms and solutions are still unclear. This review mainly explores the possible mechanisms oft rituximab resistance and current new effective treatments for rituximab resistance in DLBCL.
Related Concept Videos
Treatment Resistant Cancers
Diffusion
Diffusion
Resistivity
Resistance
Facilitated Diffusion
In this process, substrates such as organic compounds and ions interact with a transporter on one side, triggering conformational changes in proteins that enable...

